Manning & Napier Advisors LLC boosted its stake in shares of Allergan PLC. (NYSE:AGN) by 50.5% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 18,035 shares of the company’s stock after buying an additional 6,055 shares during the period. Manning & Napier Advisors LLC’s holdings in Allergan PLC. were worth $4,384,000 as of its most recent SEC filing.
A number of other institutional investors also recently modified their holdings of the company. Israel Discount Bank of New York bought a new position in shares of Allergan PLC. during the first quarter valued at approximately $988,000. Trust Co. of Vermont raised its stake in Allergan PLC. by 62.8% in the first quarter. Trust Co. of Vermont now owns 2,875 shares of the company’s stock valued at $687,000 after buying an additional 1,109 shares during the last quarter. Capital Planning Advisors LLC raised its stake in Allergan PLC. by 79.3% in the first quarter. Capital Planning Advisors LLC now owns 3,674 shares of the company’s stock valued at $878,000 after buying an additional 1,625 shares during the last quarter. BKD Wealth Advisors LLC acquired a new stake in Allergan PLC. during the first quarter valued at about $219,000. Finally, First Long Island Investors LLC acquired a new stake in Allergan PLC. during the first quarter valued at about $4,826,000. 83.63% of the stock is owned by hedge funds and other institutional investors.
Allergan PLC. (NYSE AGN) traded down 0.35% during midday trading on Friday, reaching $223.99. 2,006,235 shares of the company’s stock were exchanged. The company has a 50 day moving average price of $243.31 and a 200 day moving average price of $238.68. Allergan PLC. has a 12 month low of $184.50 and a 12 month high of $256.80. The company has a market cap of $74.88 billion, a P/E ratio of 6.82 and a beta of 1.16.
Allergan PLC. (NYSE:AGN) last posted its quarterly earnings data on Thursday, August 3rd. The company reported $4.02 earnings per share for the quarter, topping the consensus estimate of $3.95 by $0.07. The firm had revenue of $4.01 billion for the quarter, compared to analysts’ expectations of $3.95 billion. Allergan PLC. had a return on equity of 7.37% and a net margin of 79.17%. The company’s quarterly revenue was up 8.8% compared to the same quarter last year. During the same quarter last year, the business earned $3.35 EPS. On average, equities analysts anticipate that Allergan PLC. will post $16.27 EPS for the current year.
The business also recently declared a quarterly dividend, which will be paid on Friday, September 15th. Investors of record on Friday, August 18th will be given a $0.70 dividend. This represents a $2.80 dividend on an annualized basis and a dividend yield of 1.25%. The ex-dividend date of this dividend is Wednesday, August 16th. Allergan PLC.’s payout ratio is currently 9.95%.
Several research analysts have recently weighed in on the stock. BidaskClub downgraded shares of Allergan PLC. from a “hold” rating to a “sell” rating in a research note on Thursday. Argus reiterated a “buy” rating and set a $280.00 price objective on shares of Allergan PLC. in a research note on Monday, August 14th. UBS AG restated an “outperform” rating and issued a $275.00 price target on shares of Allergan PLC. in a research report on Wednesday, August 9th. Deutsche Bank AG restated a “buy” rating and issued a $278.00 price target (up from $273.00) on shares of Allergan PLC. in a research report on Wednesday, August 9th. Finally, Wells Fargo & Company reaffirmed an “outperform” rating and issued a $280.00 price objective (up previously from $270.00) on shares of Allergan PLC. in a report on Wednesday, August 9th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and fifteen have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $275.49.
Allergan PLC. Company Profile
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.